Mammary Tumors In Dogs Research Articles

Molecular Markers in Canine Mammary Tumors

Abstract Canine mammary tumors (CMTs) are one of the most common neoplasms in female dogs. Unfortunately, the current diagnosis often occurs in later stages, and there is a pressing need for more comprehensive data on treatment options to improve overall prognosis. Consequently, the early detection of these tumors is critical for improving treatment outcomes and survival rates. As such, biomarkers are essential for improving the diagnosis, treatment, and prognosis of CMT, the reason for which further research is required to enhance our understanding of the disease. The most studied biomarkers for CMT are evaluated from serum and tissue samples using different molecular approaches and relate to proliferation and cell cycle. Several biomarkers were also described regarding cell damage, autophagy and apoptotic-related pathways, hypoxia, angiogenesis, EMT, invasion, metastasis or cancer stem features. Overall, biomarkers have shown the potential to be used as a tool for the early detection of mammary tumors in dogs. However, more research is needed to validate these biomarkers and to develop sensitive and specific diagnostic tests. In this regard, we aimed to review known biomarkers and their role in CMT comprehensively. We also encouraged further investigations of reliable biomarkers that could improve treatment outcomes and survival rates for dogs with this disease.

Evaluation and Comparison of Different Surgico-chemotherapeutic Regimens for the Treatment of Malignant Canine Mammary Tumours

Background: Cancer has been regarded as the most dreaded disease for both human and animals because of its incurability. Canine mammary tumours are common and major problem encountered by academicians and practicing veterinarians. As a result, the current study was conducted to examine the effectiveness and overall impact of different surgico-chemotherapeutic approaches in treating malignant mammary tumors in dogs. Methods: The investigation involved 18 clinical instances of mammary tumors in different breeds, regardless of age or sex and were divided into three groups of six animals each. In Group S, only surgical excision of tumour was performed while animals of Group SD and Group SV were treated with surgical excision followed by administration of Doxorubicin (30 mg/m2) BSA and Vincristine sulphate (0.025 mg/kg) intravenously alongwith DNS at 7th and 14th post-operative days respectively. Different physiological and haemato-bichemical parameters i.e. Hb, PCV, TLC, TPC, DLC, Serum glucose, TSP, SUN, SC, ALT, AST and ALP were recorded preoperatively, postoperatively and following chemotherapy at 10th, 30th and 60th day intervals. Result: The present study showed transient change in the physiological, haematological and biochemical profiles following surgery and chemotherapy treatment. The histopathological analysis showed more cases of adenocarinoma which were followed by mixed carcinoma. Surgery combined with chemotherapy (doxorubicin and vincristine) resulted in minimal to no reoccurrence with few adverse reactions including inappetance, vomition, anaemia and alopecia. It was concluded that the most effective treatment for malignant mammary tumors in dogs is surgical excision followed by sequential vincristine therapy, which efficiently regresses the tumor without causing relapse.

Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.

In recent years, many studies have focused their attention on the dog as a proper animal model for human cancer. In dogs, mammary tumors develop spontaneously, involving a complex interplay between tumor cells and the immune system and revealing several molecular and clinical similarities to human breast cancer. In this review, we summarized the major features of canine mammary tumor, risk factors, and the most important biomarkers used for diagnosis and treatment. Traditional therapy of mammary tumors in dogs includes surgery, which is the first choice, followed by chemotherapy, radiotherapy, or hormonal therapy. However, these therapeutic strategies may not always be sufficient on their own; advancements in understanding cancer mechanisms and the development of innovative treatments offer hope for improved outcomes for oncologic patients. There is still a growing interest in the use of personalized medicine, which should play an irreplaceable role in the research not only in human cancer therapy, but also in veterinary oncology. Moreover, immunotherapy may represent a novel and promising therapeutic option in canine mammary cancers. The study of novel therapeutic approaches is essential for future research in both human and veterinary oncology.

Mammary Tumors in dogs: Age, Breed, Gender, Rearing, and Diet Factors

Mammary Tumors in dogs: Age, Breed, Gender, Rearing, and Diet Factors

Immunohistochemical Study of MMP-9 Expression in Canine Malignant Mammary Tumors

A class of proteinases called matrix metalloproteinases (MMPs) is involved in the breakdown of the extracellular matrix (ECM) as well as other biological activities. Due to their capacity to degrade the matrix, they were considered in the invasion and metastasis of tumors. The primary goal of this study is to evaluate the association between MMP-9 expression in tumor-adjacent stromal cells and malignant mammary tumors in dogs, as well as the potential use of this protease as a predictive tumor marker. During surgery and necropsy, 32 canine malignant mammary gland tumors were discovered. For histopathological grading of tumors, the Pena et al. [1], approach and the Goldsmith et al. [2], method were employed. Utilizing immunohistochemical labeling, epithelial and stromal cell MMP-9 expression was identified. The level of tumor malignancy was associated with the degree of MMP-9 expression in stromal cells. In addition, stromal cells had much greater levels of MMP-9 expression. The expression of MMP-9 was well distributed and intense in all grade II and III carcinomas as well as poorly differentiated carcinosarcomas. High histologic grade tumors have greater levels of MMP-9 expression, according to semiquantitative examination of the gene’s expression. This finding lends credence to the concept that MMP-9 functions as an ECM component in tumor invasion and metastasis.

Intraoperative thermal mapping of mammary tumors in dogs.

In this study, videothermometry's application in detecting mammary tumors in dogs is explored in-depth. The research hypothesizes that this technique can effectively identify cancerous tissues during surgery by analyzing thermal patterns. The methodology involved comparing thermal imaging results from dogs with palpable mammary nodules against a control group, focusing on capturing real-time thermal patterns. Results were significant, showing distinct thermal patterns in carcinomas. This indicates videothermometry's capability in accurately identifying micro metastases and differentiating between neoplastic and non-neoplastic changes. The study concludes that videothermometry has considerable potential in enhancing surgical precision, especially in tumor resection and safety margin definition, but emphasizes the need for further research to thoroughly understand the thermal signatures of various mammary tumors in dogs.

Mammary Tumors in Dogs, Recent Perspectives and Antiangiogenesis as a Therapeutic Strategy: Literature Study

A particular type of tumor that is frequently detected in female dogs who are sexually active is a mammary tumor. Neoplasia results from DNA-based alterations in cell cycle regulating genes. The mammary gland is prone to the formation of tumors due to its dynamic structure. The development of this tumor is supported by numerous variables. It has been recently discovered that there is substantial evidence linking the BRCA2 gene to the process of cancer. Standard examination techniques, such as fine needle aspiration, histopathology, and immunohistochemistry, are used along with ancillary tests to determine the tumor type and degree of malignancy. The primary treatment option for malignant tumors is surgical resection followed by adjuvant chemotherapy; benign tumors necessitate surgical resection as well. Adjuvant therapy options include hormone therapy and non-steroidal anti-inflammatory medications. Tumor tissue undergoes angiogenesis as it grows and develops to accommodate the abundant supply of nutrients. Therefore, angiogenesis-inhibiting therapies can be utilized to halt the growth of tumor cells. A number of antiangiogenic medications are now being studied in clinical settings on humans, and several more are undergoing trials on animals. In addition to pharmaceuticals, viruses may be used as a therapeutic to block tumor angiogenesis.

Identifying the Risk Factors for Malignant Mammary Tumors in Dogs: A Retrospective Study.

Mammary cancer is one of the main causes of death in female dogs worldwide, considering that many risk factors are involved in its development. This study aimed to elucidate the relationship between epidemiological and clinical risk factors with the histopathological diagnosis of malignant mammary tumors in dogs treated at the Veterinary Hospital of the Federal University of Uberlândia, which has one of the first veterinary oncology services in Brazil. A retrospective matched case-control study was conducted to identify risk factors for the development of malignant mammary tumors in dogs. The variables analyzed were size dog, breed, housing, type of diet, and body score. Potential risk factors were selected by univariate analysis (p < 0.25) before multivariate forward binary logistic regression. The most frequent benign tumor was the benign mixed tumor (35.2%), and the most frequent malignant tumor was the mixed carcinoma (27.4%). Size dog, breed, housing, and overweight are predictors of malignant mammary tumors in dogs. The highest risk of developing malignant mammary tumors is associated with large female dogs, Yorkshire or Poodle breeds, living outside the home, or being overweight.

Classification and Diagnosis of Mammary Tumors in Dogs Using Deep Learning Techniques

Classification and Diagnosis of Mammary Tumors in Dogs Using Deep Learning Techniques

Prognostic value of different forms of serum MMP-2 and MMP-9 in dogs with mammary tumors; a longitudinal study

Gelatinases (MMP-2 and MMP-9) are related to tumor invasion and metastasis. In humans, the diagnostic value of serum levels of gelatinases has been confirmed in breast cancer, but their diagnostic value in canine mammary tumors is still unknown. This study aimed to determine the serum level of gelatinases in dogs with mammary tumors in order to determine their value in the diagnosis of malignancy or benign tumors and also in predicting the possibility of metastasis and recurrence. Frequent measurement of MMP-2 and MMP-9 by gelatin zymography in serum before and after surgical treatment has not previously been studied for monitoring mammary tumors in dogs. Thus, the serum levels of MMP-2 and MMP-9 in 26 dogs with mammary tumors before surgical treatment and then 1, 4 and 12 months after surgery were evaluated by gelatin zymography. Serum samples of 26 healthy dogs with normal conditions were used as control.Dogs with benign and malignant mammary tumors showed bands of pro-MMP-2, pro-MMP-9 and active MMP-9. However, only pro-MMP-2 and pro-MMP-9 bands appeared in the serum of control group. Our results showed that the presence of active MMP-9, regardless of its level, was prognostically important for metastasis and or recurrence (M/R). However, the presence of active MMP-2 band was more important for M/R than active MMP-9, as its presence coincides with definitive M/R. It seems that serum gelatin zymography could possibly be used at regular intervals before and after surgery to evaluate the probability of M/R in dogs with mammary tumors. More research is needed in this regard.

Carcinoma tubulopapilar en gato: Reporte de un caso

Breast tumors in cats rank third in the series of tumors diagnosed in this species. About half of mammary tumors in dogs are malignant, whereas in cats, the odds reach 90%, which makes a detailed examination of the mammary chain essential, especially in cases of animals submitted to simple mastectomies with a history of tumors. This study will aim to analyze the clinical and anatomopathological aspects of a case of tubulopapillary carcinoma in a cat, mixed-breed, 9 years old, white coat, spayed. The animal was admitted to the Veterinary Hospital in the city of Bayeux, Paraíba, with a history of nodulation in the left abdominal breast, and circumscribed volume increase with a cystic aspect in the subcutaneous tissue in the neighboring region. Puncture of the subcutaneous cyst revealed a large volume of a viscous light-yellow-colored liquid, which was centrifuged and prepared in slides stained with rapid panoptic for cytological analysis. The anatomopathological study proposes to build information on the histogenesis of this tumor as well as its morphology, and thus contribute to the clinical oncology of felines with regards to tumor staging and increased patient survival.

Modern Imaging Techniques in the Study and Disease Diagnosis of the Mammary Glands of Animals.

The study of the structure and function of the animals' mammary glands is of key importance, as it reveals pathological processes at their onset, thus contributing to their immediate treatment. The most frequently studied mammary diseases are mastitis in cows and ewes and mammary tumours in dogs and cats. Various imaging techniques such as computed tomography, positron emission tomography, magnetic resonance imaging, and ultrasonographic techniques (Doppler, contrast-enchanced, three-dimensional and elastography) are available and can be applied in research or clinical practice in order to evaluate possible abnormalities in mammary glands, as well as to assist in the differential diagnosis. In this review, the above imaging technologies are described, and the perspectives of each method are highlighted. It is inferred that ultrasonographic modalities are the most frequently used imaging techniques for the diagnosis of clinical or subclinical mastitis and treatment guidance on a farm. In companion animals, a combination of imaging techniques should be applied for a more accurate diagnosis of mammary tumours. In any case, the confirmation of the diagnosis is provided by laboratory techniques.

GATA-3 expression and its correlation with prognostic factors and survival in canine mammary tumors.

The transcription factor GATA-3 plays a significant role in mammary gland development and differentiation. Recent studies on human oncology have demonstrated its association with favorable pathologic factors in breast cancer. Canine mammary tumours, proposed as comparative and translational study models, have epidemiological, clinical, biological, and genetic characteristics similar to those of human breast cancers. Here, we evaluated the frequency of GATA-3 expression in mammary tumors of dogs and its relationship with prognostic factors and survival. Tumor samples were obtained from 40 female dogs and grouped according to histological type into benign tumors (n = 10), carcinoma in mixed tumors (CMTs) (n = 20), and aggressive tumors (n = 10). CMTs were further separated according to histological grade, and data on clinical staging and diagnosis, histopathological grading, and survival rate were collected. GATA-3 and estrogen receptor (ER) expression were higher in benign and well-differentiated carcinomas than in aggressive tumors, which showed greater Ki-67 expression. The expression rate of ER in the studied groups was equivalent to that of GATA-3. We identified a strong positive correlation between GATA-3 and ER expression frequencies and a negative correlation between those of GATA-3 and Ki-67. There were associations between GATA-3 (p < 0.001), Ki-67 (p = 0.003), tumor size (p < 0.001), clinical stage (p = 0.002), lymph node metastasis (p < 0.001), and histological grade (p < 0.001) by univariate survival analysis. The parameters ER (p = 0.015) and GATA-3 (p = 0.005) also influenced survival in a multifactorial manner. Kaplan-Meier analysis of survival curves validated our previous findings that dogs with GATA-3 expression in ≥79.4% of cells had significantly higher survival rates (p < 0.001). The performance analysis showed that the expression of GATA-3 in ≥79.4% of cells effectively predicted survival or death in dogs with mammary tumors. Collectively, these results suggest that GATA-3 can be a relevant marker in the study of mammary tumor progression and has potential as a prognosis marker for predicting outcomes in canine mammary tumors.

Canine Mammary Tumor Cell Lines Derived from Metastatic Foci Show Increased RAD51 Expression but Diminished Radioresistance via p21 Inhibition.

Due to the high incidence of mammary tumors in dogs, it is important to elucidate the pathogenesis of these tumors in veterinary medicine. Radiation therapy is often used to treat mammary tumors that target DNA lesions. RAD51 is a key molecule that repairs DNA damage via homologous recombination. We examined the relationship between RAD51 expression and radiosensitivity in mammary tumor cell lines. CHMp and CHMm from the same individual were selected based on the differences in RAD51 expression. The radiosensitivity of both cell lines was examined using MTT and scratch assays; CHMm, which has high RAD51 expression, showed higher sensitivity to radiation than CHMp. However, the nuclear focus of RAD51 during DNA repair was formed normally in CHMp, but not in most of CHMm. Since irradiation resulted in the suppression of cell cycle progression in CHMp, the expression of p21, a cell cycle regulatory factor, was detected in CHMp after 15 Gy irradiation but not in CHMm. These results indicate that functional expression is more important than the quantitative expression of RAD51 in canine mammary tumor cells in response to DNA damage.

A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer

Mammary tumors in dogs hold great potential as naturally occurring breast cancer models in translational oncology, as they share the same environmental risk factors, key histological features, hormone receptor expression patterns, prognostic factors, and genetic characteristics as their human counterparts. We aimed to develop in vitro tools that allow functional analysis of canine mammary tumors (CMT), as we have a poor understanding of the underlying biology that drives the growth of these heterogeneous tumors. We established the long-term culture of 24 organoid lines from 16 dogs, including organoids derived from normal mammary epithelium or benign lesions. CMT organoids recapitulated key morphological and immunohistological features of the primary tissue from which they were derived, including hormone receptor status. Furthermore, genetic characteristics (driver gene mutations, DNA copy number variations, and single-nucleotide variants) were conserved within tumor-organoid pairs. We show how CMT organoids are a suitable model for in vitro drug assays and can be used to investigate whether specific mutations predict therapy outcomes. Specifically, certain CMT subtypes, such as PIK3CA mutated, estrogen receptor-positive simple carcinomas, can be valuable in setting up a preclinical model highly relevant to human breast cancer research. In addition, we could genetically modify the CMT organoids and use them to perform pooled CRISPR/Cas9 screening, where library representation was accurately maintained. In summary, we present a robust 3D in vitro preclinical model that can be used in translational research, where organoids from normal, benign as well as malignant mammary tissues can be propagated from the same animal to study tumorigenesis.

Evidence for heterogeneity in response to treatment in mammary tumors of dogs as happens in humans.

Tumors are formed by various clones developed over a long time. This gives rise to a heterogeneous nature. This heterogeneity is the hardest challenge in the treatment of cancers because it is the main reason for drug resistance. This is a well-known fact in human cancer. Therefore, we have reasoned that if the tumor heterogeneity in canine mammary gland tumors (CMGTs) could be shown by an ex vivo assay, which will be used first time in veterinary oncology practice, this could be used further in clinics. To achieve this, twenty-six patients were included in the study. Tumor tissues were obtained from animals during routine surgery. Tumor cells were isolated and seeded ex vivo. The cells were exposed to anticancer drugs that are clinically used. Seven days after the treatment, chemosensitivity has luminometrically been assayed by ATP-tumor chemosensitivity assay (ATP-TCA). It has clearly been shown that all the tumor tissues have responded to treatment differently, implying that heterogeneity exists in mammary tumors. There has also been found that there was a weak to moderate statistically significant correlation between tumor size and drug index. However, there has been no correlation between drug index and metastasis to lymph nodes. Hyperplasic areas had relatively higher PCNA values. The results of our study demonstrate the heterogeneity in responses to in vitro drugs. Clinical trials based on test results and follow-up studies with large numbers of animals are needed to prove that such chemotherapeutic activity assessment tests can be clinically useful in predicting drug responses in CMGTs.

Classification and Diagnosis of Mammary Tumors in Dogs Using Deep Learning Techniques

Classification and Diagnosis of Mammary Tumors in Dogs Using Deep Learning Techniques

Solitary and multiple simultaneous malignant epithelial mammary tumours in dogs: An explorative retrospective study

Canine mammary tumours represent a hard-prognostic task for veterinary clinicians. TNM staging and grading systems refer to a single tumour. Significant limits come to light when these systems are applied to multiple mammary tumours due to the arbitrary criterion in determining which single tumour is representative of the patient's prognosis. This study explored some clinical features of 50 dogs affected by at least one malignant mammary tumour. Clinical features and staging, together with histological classification and grading, have been related to disease-free survival (DFS) with the purpose to evaluate their impact on prognosis. The prognosis was worse in 10-11-year-old dogs (P < 0.05), in dogs affected by complex carcinoma (P < 0.05), and in patients assigned to Peña grade I (P < 0.05). The bodyweight was not linearly related to DFS (P < 0.01), and patients with a low number of neoformations (n ≤ 2) showed a better prognosis than dogs with 3–5 tumours (P < 0.05). Both the average and the total size of malignant tumours were related to DFS (P < 0.05). Dogs assigned with stage I had the best DFS (P < 0.05).In conclusion, the Peña grade I alone would not seem to guarantee a favourable prognosis when applied to mammary tumours in dogs affected by multiple simultaneous presentations. Different characteristics, besides tumour grading, such as tumour immunophenotype and expression of hormonal receptors, could in the future, contribute to elucidate the clinical behaviour of multiple canine mammary tumours.

Electrocardiography in Bitches with Mammary Tumors

Background: The incidence of cancer has increased due to greater longevity of the animals as a consequence of better control of other diseases, improvement of nutrition and good practices in preventive medicine. Malignant tumors can cause paraneoplastic syndrome as hypercalcemia, anemia, cachexia, among others and consequent cardiovascular disorders. The electrocardiography (ECG) is a complementary exam that can reveal with its traces these rhythms disorders. Based on that, the objective of this study was to evaluate the ECG in bitches with mammary tumors in order to detect in which type of tumor would be found significant changes as in cardiac rhythm, ECG waves, segments or cardiac axis.Material, Methods &amp; Results: Twenty-nine female dogs were used in this study, being 19 bitches with mammary tumor, and they were allocated in three groups: G1: control group (n=10), G2: benign neoplasia group (n=6) and G3: malignant neoplasia group (n=13). The most prevalent type of neoplasia in G2 was the benign mixed tumor (83%), followed by adenoma (17%) whereas in G3: carcinoma in mixed tumor (61%); papillary carcinoma (23%). Regarding cardiac rhythm, it was found sinus arrhythmia (SA) and normal sinus rhythm (NS): G1: 50% SA and 50% NS; G2: 67% SA and 33% NS; G3: 54% SA and 46% NS. No ventricular or atrial arrhythmias were detected. For other parameters in G1, G2 and G3, respectively (mean±Std error): FC (bpm): 110±9.2, 120±8.5, 124±7,5; P (ms): 48±1.6, 51±1.8, 50±1.2; P (mV) 0.19±0.02, 0,2±0.02, 0,19±0.02; PR (ms): 94±4.3, 93±5.5, 89±3.9; QRS (ms): 56±1.54, 60±4, 62±1.2; R (mV): 1.1±0.06, 1.2±0.24, 0.9±0.13; QT (ms): 203±9.4; 204±7.9; 182±15.6; and cardiac axis (°): 66±6.2, 61±7.9, 70±7.5. There were no significant differences for all cardiac parameters and also for ST interval and T wave morphology.Discussion: All electrocardiographic parameters found are in accordance with other studies carried out in the canine species. The results regarding tumor types differ from what was found in another study, in which in 18 bitches with mammary tumors, 55% were benign, with prevalence of adenomas (38%) followed by benign mixed tumors, and 45% malignant, with adenocarcinoma prevailing (22%). In another study, it was verified in 63 bitches the predominance of tubular carcinoma (26.56%) and carcinoma in mixed tumor (23.44%). Diverging from the electrocardiographic parameters of this study, a significant difference was found in the R wave amplitude value in the research by Barros et al., (2015) who performed computerized electrocardiography in 50 dogs, not only with mammary neoplasms (55% mammary carcinomas), but also in mastocytomas, lymphomas, benign tumors and other sarcomas. This author found out that the R wave amplitude values of the neoplasia group were lower when compared to the control group. In addition, we suspect that other types of tumors could result in more paraneoplastic syndrome than the mammary neoplasms found in this research. Neoplasms as lymphomas (T cells), apocrine gland anal sac adenocarcinomas, multiple myelomas and thymomas are known as a cause of hypercalcemia of malignancy and histiocytic sarcomas, myelomas, leukemia and lymphomas causing anemia. In conclusion, ECG has no changes in benign or malignant mammary tumors in dogs. However, this fact does not exclude the importance of its performance in pre-anesthetic evaluations.

Nuclear morphometry of mammary tumors of dogs and histopathological diagnosis

For dog’s mammary tumors diagnostics scientists need researches, which can adopt and use methods developed for humans. The aim of this research paper is to set the inter relation between the parameters of nuclear morphometry (nuclear area, diameter, perimeter) and histopathological type of mammary tumors of dogs. Animals aged from 6 to 12 (medium meaning 9.2 ± 1.6 years). According to histopathological research 3 tumors were benign and 25 were malignant, 18 of them – malignant epithelial neoplasms (3 tubular carcinomas, 13 tubulopapillary carcinomas, 1 cystic-papillary carcinoma, 3 colid carcinomas, 1 micropapillary carcinoma), 3 malignant epithelial neoplasms of special type (mucinous, lipid-rich, spindle cell carcinomas) and 4 malignant mesenchymal neoplasms (chondrosarcoma). Nuclear morphometry parameters (nuclear area, perimeter and diameter) of benign tumours (20.48 ± 1.22, 19.13–21.50 µm2; 19.27 ± 0.10, 19.17–19.36 µm and 5.09 ± 0.16, 4.92–5.22 µm) were probably smaller than in malignant tumours, for example in simple carcinoma (38.61 ± 5.61, 29.26–46.16 µm2; 26.42 ± 2.32, 22.10–29.60 µm and 6.96 ± 0.52, 6.03–7.62 µm), tubular (37.89 ± 7.30, 29.94–46.16 µm2, 26.34 ± 2.83, 22,98–29,60 µm and 6.90 ± 0.70, 6.16–7.62 µm), tubulopapillary (40.22 ± 3.48, 34.38–44.75 µm2, 27.02 ± 1.49, 24.41–28.97 µm and 7.12 ± 0.31, 6.58–7.52 µm), colid (43.57 ± 5.54, 37.71–48.73 µm2, 28.05 ± 1.88, 26.54–30.15 µm and 7.41 ± 0.47, 6.91–7.85 µm), other malignant epithelial neoplasms (39.99 ± 5.15, 29.94–48.73 µm2; 26.85 ± 2.03, 22.98–30.15 µm and 7.09 ± 0.50, 6.16–7.85 µm) and malignant epithelial neoplasms of special types (45.89 ± 4.12, 43.41–50.65 µm2; 29.92 ± 0.21, 29.68–30.06 µm and 7.60 ± 0.34, 7.41–8.00 µm). However, there was not statistically significant difference in comparison between benign tumours and sarcomas (25.95 ± 5.21, 21.64–33.00 µm2; 21.85 ± 1.79, 20.21–24.05 µm and 5.68 ± 0.56, 5.21–6.42 µm). Among the different groups of malignant neoplasms lower rates were in sarcoma, the other groups had no difference. Taking into consideration the indicators of nuclear morphometry (nuclear area, diameter and perimeter) different types of neoplasms can be differentiated: benign from malignant tumours and sarcomas from malignant epithelial neoplasms (tubular, tubulopapillary, cystic-papillary, colid, micropapillary, mucinous, lipid-rich and spindle cell carcinomas).